Identification of Biological Targets of Therapeutic Intervention for Diabetic Nephropathy with Bioinformatics Approach

Abstract

We aimed to discover the potential microRNA (miRNA) targets for diabetic nephropathy (DN) treatment. The microarray data of GSE1009 was downloaded from Gene Expression Omnibus (GEO) database. The differentially expressed genes (DEGs) between DN patients and normal individuals were analyzed using limma package. The significant miRNAs targeting DEGs were collected based on Web-based Gene Set Enrichment Analysis Toolkit (WebGestalt) system. Then we predicted the protein-protein interaction (PPI) pairs regulated by significant miRNAs and constructed the PPI pairs-miRNA network using Cytoscape software. Besides, the significant function modules were explored using Molecular Complex Detection (MCODE) and Biological Networks Gene Ontology (BiNGO) plugin. Total 752 DEGs were obtained, including 318 down-regulated ones and 434 up-regulated ones. There were 10 significant miRNAs, among which miRNA-25 was the most significant. The PPI pairs-miRNA network was established with 103 PPI pairs and 10 miRNAs. Three function modules were obtained, including module A involved with miRNA-29, module B with miRNA-106 and module C with miRNA-124A and miRNA-21B. MiRNA-25, 29, 124 and 21 play key roles in DN progression and these miRNAs may be potential targets for DN treatment.

Key words

diabetic nephropathy - microarray data - differential expression genes - protein pairs - microRNAs

• References

• 1 Keen H, Viberti G. Genesis and evolution of diabetic nephropathy. Journal of clinical pathology 1981; 34: 1261-1266
• 2 Deckert T, Poulsen J. Diabetic nephropathy: fault or destiny?. Diabetologia 1981; 21: 178-183
• 3 Keen H, Track N, Sowry G. Arterial pressure in clinically apparent diabetics. Diabète & métabolisme 1975; 1: 159
• 4 Young BA, Maynard C, Boyko EJ. Racial differences in diabetic nephropathy, cardiovascular disease, and mortality in a national population of veterans. Diabetes Care 2003; 26: 2392-2399
• 5 Soldatos G, Cooper M. Diabetic nephropathy: important pathophysiologic mechanisms. diabetes research and clinical practice 2008; 82: S75-S79
• 6 Lin W-Y, MY-P Yeh, Tseng T-L et al. Urine and serum biomarkers associated with diabetic nephropathy. 2013 Google Patents
• 7 Alvarez M, Distefano J. Towards microRNA-based therapeutics for diabetic nephropathy. Diabetologia 2013; 56: 444-456
• 8 Wang Q, Wang Y, Minto AW et al. MicroRNA-377 is up-regulated and can lead to increased fibronectin production in diabetic nephropathy. The FASEB Journal 2008; 22: 4126-4135
• 9 Kato M, Zhang J, Wang M et al. MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-β-induced collagen expression via inhibition of E-box repressors. Proceedings of the National Academy of Sciences 2007; 104: 3432-3437
• 10 Putta S, Lanting L, Sun G et al. Inhibiting microRNA-192 ameliorates renal fibrosis in diabetic nephropathy. Journal of the American Society of Nephrology 2012; 23: 458-469
• 11 Baelde HJ, Eikmans M, Doran PP et al. Gene expression profiling in glomeruli from human kidneys with diabetic nephropathy. American journal of kidney diseases 2004; 43: 636-650
• 12 Troyanskaya O, Cantor M, Sherlock G et al. Missing value estimation methods for DNA microarrays. Bioinformatics 2001; 17: 520-525
• 13 Fujita A, Sato JR, Rodrigues LO et al. Evaluating different methods of microarray data normalization. Bmc Bioinformatics 2006; 7: 469
• 14 Smyth GK. Limma: linear models for microarray data, in Bioinformatics and computational biology solutions using R and Bioconductor. 2005. Springer; 397-420
• 15 Yekutieli D, Benjamini Y. Resampling-based false discovery rate controlling multiple test procedures for correlated test statistics. Journal of Statistical Planning and Inference 1999; 82: 171-196
• 16 Zhang B, Kirov S, Snoddy J. WebGestalt: an integrated system for exploring gene sets in various biological contexts. Nucleic acids research 2005; 33: W741-W748
• 17 Duncan D, Prodduturi N, Zhang B. WebGestalt2: an updated and expanded version of the Web-based Gene Set Analysis Toolkit. Bmc Bioinformatics 2010; 11: P10
• 18 Szklarczyk D, Franceschini A, Kuhn M et al. The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored. Nucleic acids research 2011; 39: D561-D568
• 19 Tanzer A, Stadler PF. Molecular evolution of a microRNA cluster. Journal of molecular biology 2004; 339: 327-335
• 20 Bader GD, Hogue CW. An automated method for finding molecular complexes in large protein interaction networks. Bmc Bioinformatics 2003; 4: 2
• 21 Maere S, Heymans K, Kuiper M. BiNGO: a Cytoscape plugin to assess overrepresentation of gene ontology categories in biological networks. Bioinformatics 2005; 21: 3448-3449
• 22 Yang Y, Xiao L, Li J et al. Urine miRNAs: Potential biomarkers for monitoring progression of early stages of diabetic nephropathy. Medical hypotheses 2013;
• 23 Mogensen C. Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. British medical journal (Clinical research ed.) 1982; 285: 685
• 24 Natarajan R, Putta S, Kato M. MicroRNAs and diabetic complications. Journal of cardiovascular translational research 2012; 5: 413-422
• 25 Gorin Y, Block K, Hernandez J et al. H oxidase mediates hypertrophy and fibronectin expression in the diabetic kidney. Journal of Biological Chemistry 2005; 280: 39616-39626
• 26 Ago T, Kitazono T, Ooboshi H et al. Nox4 as the major catalytic component of an endothelial NAD (P) H oxidase. Circulation 2004; 109: 227-233
• 27 Gorin Y, Block K. Nox4 and diabetic nephropathy: with a friend like this, who needs enemies?. Free Radical Biology and Medicine 2013; 61: 130-142
• 28 Mao S, Huang S. The signaling pathway of NADPH oxidase and its role in glomerular diseases. Journal of Receptors and Signal Transduction 2013; 1-6
• 29 Gorin Y, Block K. Nox4 and diabetic nephropathy: With a friend like this who needs enemies. Free Radical Biology and Medicine 2013;
• 30 Fu Y, Zhang Y, Wang Z et al. Regulation of NADPH oxidase activity is associated with miRNA-25-mediated NOX4 expression in experimental diabetic nephropathy. American journal of nephrology 2010; 32: 581-589
• 31 Maurer B, Stanczyk J, Jüngel A et al. MicroRNA-29, a key regulator of collagen expression in systemic sclerosis. Arthritis & Rheumatism 2010; 62: 1733-1743
• 32 Cho ME, Smith DC, Branton MH et al. Pirfenidone slows renal function decline in patients with focal segmental glomerulosclerosis. Clinical Journal of the American Society of Nephrology 2007; 2: 906-913
• 33 Ramachandrarao SP, Zhu Y, Ravasi T et al. Pirfenidone is renoprotective in diabetic kidney disease. Journal of the American Society of Nephrology 2009; 20: 1765-1775
• 34 Wang B, Komers R, Carew R et al. Suppression of microRNA-29 expression by TGF-β1 promotes collagen expression and renal fibrosis. Journal of the American Society of Nephrology 2012; 23: 252-265
• 35 Boye E, Mollet G, Forestier L et al. Determination of the genomic structure of the COL4A4 gene and of novel mutations causing autosomal recessive Alport syndrome. The American Journal of Human Genetics 1998; 63: 1329-1340
• 36 Buzza M, Dagher H, Wang YY et al. Mutations in the COL4A4 gene in thin basement membrane disease. Kidney international 2003; 63: 447-453
• 37 Voskarides K, Damianou L, Neocleous V et al. COL4A3/COL4A4 mutations producing focal segmental glomerulosclerosis and renal failure in thin basement membrane nephropathy. Journal of the American Society of Nephrology 2007; 18: 3004-3016
• 38 Karihaloo A. Anti-fibrosis therapy and diabetic nephropathy. Current Diabetes Reports 2012; 12: 414-422
• 39 Yang Y, Xiao L, Li J et al. Urine miRNAs: potential biomarkers for monitoring progression of early stages of diabetic nephropathy. Med Hypotheses 2013; 81: 274-278
• 40 Dong H, Lei J, Ding L et al. MicroRNA: function, detection, and bioanalysis. Chemical reviews 2013; 113: 6207-6233